TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24866329
Drug: mitiglinide/voglibose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: mitiglinide/voglibose combination
Study: 22306193
Drug: AZD1236 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1236 75 mg twice daily for 6 weeks
Study: 16550603
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered intravenously (IV, 100 mg/m2)
Study: 16550603
Drug: Cisplatin administered
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered intra-arterially (IA, 150 mg/m2)
Study: 12491212
Drug: Minocycline-ethylenediaminetetraacetate (M-EDTA)
Normalized name: ethylenediaminetetraacetate
DrugBank: Edetic acid (DB00974)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline-ethylenediaminetetraacetate (M-EDTA) lock solution
Study: 12491212
Drug: Heparin flush
Normalized name: heparin flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flush (Control)
Study: 1756285
Drug: Otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilonium bromide (OB) 40 mg tid
Study: 7017982
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg IV every 6 hours
Study: 7017982
Drug: Antacid titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid titration to maintain gastric pH > 4.0
Study: 19641042
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemoradiation in SCCHN patients (TAX 324 trial)
Study: 9783350
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day sertraline
Study: 9783350
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day imipramine
Study: 3279969
Drug: Complamin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complamin (1 g t.i.d.)
Study: 3279969
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g b.i.d.)
Study: 3279969
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Complamin and cholestyramine
Study: 23587943
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) with primaquine (0.75 mg/kg) on day 2
Study: 21512491
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of IRS 19
Study: 21512491
Drug: Irrigation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation of the nasopharynx with saline solutions
Study: 17002812
Drug: Unilateral lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral lower limb suspension (ULLS) for 20 days
Study: 11672942
Drug: Oral flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flupenthixol (2.5 or 5.0 mg; p.o.)
Study: 11672942
Drug: Intramuscular flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular flupenthixol decanoate (10 or 20 mg; i.m.)
Study: 11672942
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose flupenthixol
Study: 3034040
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 to 10 mg daily) - once-daily administration
Study: 3034040
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 to 10 mg daily) - twice-daily administration
Study: 3034040
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 to 10 mg daily)
Study: 29354931
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (EA + Mulligan's mobilization)
Study: 27319970
Drug: ABT‐126 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐126 50 mg
Study: 23660378
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (AA + lipid group)
Study: 23660378
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (high AA + lipid group)
Study: 23660378
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g AA kg(‐1) · d(‐1) (control group)
Study: 21908683
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa inhibitor
Study: 21908683
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with abciximab and Angioguard(®) embolic protection
Study: 7999812
Drug: Intraperitoneal antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal antibiotics (Cephalothin, cefazolin, vancomycin, ceftazidime, aminoglycosides tobramycin and gentamicin)
Study: 7999812
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy
Study: 7999812
Drug: Initial intraperitoneal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intraperitoneal therapy for both gram-positive and gram-negative bacteria
Study: 3057482
Drug: Dextropropoxyphene (DXP)
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene (DXP) 130 mg
Study: 3057482
Drug: Dextropropoxyphene (DXP)
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene (DXP) 65 mg + Amitriptyline (AMI) 25 mg
Study: 3057482
Drug: Indomethacin (IN)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IN) 50 mg
Study: 31757517
Drug: Lifetime history
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifetime history of injecting drug use
Study: 24285938
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/day for 8 weeks
Study: 24285938
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg/day for 8 weeks
Study: 16864110
Drug: Deoxyribonucleotidum injection
Normalized name: Adenine Deoxyribonucleoside
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deoxyribonucleotidum injection
Study: 12704355
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 30 mg (n = 464)
Study: 10634340
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with supplemental oxygen
Study: 1348061
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg, four times daily for 3 weeks
Study: 27457255
Drug: High-dose implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose implant
Study: 27457255
Drug: Low-dose implant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose implant
Study: 20179212
Drug: Siltuximab 6
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 6 mg/kg every 2 weeks
Study: 20179212
Drug: Siltuximab 9
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 9 mg/kg every 3 weeks
Study: 16224086
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group from phase III ischemic stroke therapy trials
Study: 12392866
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of administration close to study closeout
Study: 9920089
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose recombinant human LH (r-hLH) (150 IU, twice daily)
Study: 9920089
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose recombinant human LH (r-hLH) (375 IU, twice daily)
Study: 7661074
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral anticoagulant and antiplatelet therapy
Study: 2292620
Drug: Culturally sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally sensitive modeling therapy
Study: 7024156
Drug: mianserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (10 mg nocte)
Study: 24188573
Drug: Multi-level intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-level intervention to reduce antibiotic prescribing
Study: 15497908
Drug: Drospirenone (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (1, 2 or 3 mg) combined with estradiol (1 mg)
Study: 7959187
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated tablets
Study: 3496848
Drug: Cefoxitin, piperacillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin, piperacillin, cefoperazone, and aztreonam administered intravenously for 9 days
Study: 23802352
Drug: Intervention A
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention A (weekly training courses with therapy sessions)
Study: 20812020
Drug: 2 l
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l PEG combined with 36 mg senna glycosides in tablets
Study: 20812020
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l PEG
Study: 19929645
Drug: On-site provision
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site provision of implants and IUDs at Site B
Study: 15255284
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ospemifene
Study: 15255284
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ospemifene
Study: 15255284
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ospemifene
Study: 11750186
Drug: Nimodipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (90 mg)
Study: 9259934
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin for 7 days in addition to routine prophylactic intravenous ampicillin
Study: 3687352
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60 as plasma substitute, postoperative analgesia with intramuscular ketobemidone
Study: 17445811
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (CC and rFSH)
Study: 15456082
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels
Study: 10207592
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g x 2/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Study: 10207592
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g x 3/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Study: 8549245
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy radiation therapy (single fraction)
Study: 8549245
Drug: 12 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 Gy radiation therapy
Study: 8549245
Drug: 18 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 Gy radiation therapy
Study: 8549245
Drug: 24 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 Gy radiation therapy
Study: 2755259
Drug: Clebopride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (0.5 mg/kg)
Study: 2755259
Drug: Clebopride (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (0.75 mg/kg)
Study: 2755259
Drug: Clebopride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride (1 mg/kg)
Study: 2755259
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg/kg)
Study: 31638010
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single dose 20 mg/kg, administered twice a year for 2 years)
Study: 31638010
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of azithromycin (6 months apart)
Study: 31638010
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of azithromycin
Study: 31638010
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of azithromycin
Study: 27936524
Drug: Generic clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic clopidogrel product (75 mg once daily for 7 days)
Study: 27936524
Drug: Reference clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference clopidogrel product (75 mg once daily for 7 days)
Study: 26348588
Drug: Treatment-as-usual (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (medication alone)
Study: 23494740
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of GaCr milk powder
Study: 22566310
Drug: Glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.5 g/kg/day for 5 days as continuous perfusion)
Study: 18162017
Drug: 2-g E-EPA
Normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2-g E-EPA
Study: 15077311
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) at weeks 0, 2, and 6
Study: 11513820
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (10,000 lux for 30 min, from 6:00 AM to 6:30 AM)
Study: 7828189
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of riboflavin as a single oral dose for at least 3 months
Study: 7828189
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of riboflavin plus 75 mg of aspirin
Study: 2556883
Drug: RIT 4237
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIT 4237 oral rotavirus vaccine
Study: 28475671
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (dabrafenib 150 mg twice daily + trametinib 2 mg once daily)
Study: 21355147
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Piracetam tablet)
Study: 19041440
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) OCP (30 mcg EE/150 mcg DSG)
Study: 19041440
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose (VLD) OCP (20 mcg EE/150 mcg DSG)
Study: 19041440
Drug: EE-only phase
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EE-only phase (10 mcg EE) in group VLD
Study: 17953131
Drug: Drama therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drama therapy program
Study: 15372846
Drug: statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: statin monotherapy (10, 20, 40 mg/day or 80 mg/day)
Study: 11552903
Drug: Budesonide controlled
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide controlled ileal release 6 mg o.m.
Study: 11552903
Drug: Budesonide controlled
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide controlled ileal release flexible dosing (3, 6 or 9 mg o.m.)
Study: 7522721
Drug: Conventional salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional salvage therapy
Study: 7522721
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Study: 7522721
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous complete remission (cCR) with salvage therapy
Study: 23468128
Drug: Cabergoline (0.5‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5‐1 mg/week up to 3.0 mg/week) followed by ketoconazole (200 mg/day to 600 mg/day)
Study: 23468128
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg/day to 600 mg/day) followed by cabergoline (0.5‐1 mg/week up to 3.0 mg/week)
Study: 18930473
Drug: Serial sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial sleep deprivation therapy (six nights of total SD within three weeks, separated by nights of recovery sleep)
Study: 18930473
Drug: No sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sleep deprivation therapy (control group)
Study: 17086382
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy, 25 min per session, 5 days per week for 3 weeks.
Study: 17086382
Drug: Sham PEMF
Normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham PEMF therapy, 25 min per session, 5 days per week for 3 weeks.
Study: 11593723
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg.kg‐1, orally, administered 45 min before induction) in Group M
Study: 2968548
Drug: Clomiphene citrate-human
Normalized name: Clomiphene Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate-human menopausal gonadotropin combination without LH-RH analogue (control group)
Study: 31545115
Drug: Parent-focused stress
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-focused stress management intervention (four individual sessions with a community wellness coach over 3 months, supplemented with weekly text messaging and twice monthly group sessions for 6 months)
Study: 30722059
Drug: Lefamulin 150
Normalized name: lefamulin 150 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefamulin 150 mg IV every 12 hours
Study: 30722059
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg IV every 24 hours
Study: 19746673
Drug: Solubilized 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solubilized 5% BPO gel
Study: 11095452
Drug: sc insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc insulin (INS)
Study: 8341987
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and amoxycillin combination therapy (n = 30)
Study: 8341987
Drug: Omeprazole monotherapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole monotherapy (n = 30)
Study: 3088652
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg at 8 a.m.
Study: 3088652
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg at 11 p.m.
Study: 3088652
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg at 2 a.m.
Study: 3088652
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg at 5 a.m.
Study: 29488152
Drug: DS-8500a 50
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 50 mg
Study: 26934259
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/liraglutide (n=278; maximum dose, 50 U of degludec/1.8 mg of liraglutide)
Study: 26934259
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n=279; no maximum dose)
Study: 26934259
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/liraglutide
Study: 23509088
Drug: Low coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low coffee consumption (< 200 ml/day)
Study: 23509088
Drug: Moderate coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate coffee consumption (200‐450 ml/day)
Study: 23509088
Drug: High coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High coffee consumption (> 450 ml/day)
Study: 18768350
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (antihypertensive dose)
Study: 12756157
Drug: Nurse facilitator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse facilitator (supervised nurse to initiate and titrate beta-blockers)
Study: 12756157
Drug: Provider and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider and patient notification (computerized provider reminders and patient letters advocating beta-blockers)
Study: 9196608
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Study: 9196608
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (BID) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Study: 8198761
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation (Orfil retard enteric coated tablet)